ISOREA
ISOREA AB is a Swedish IVD company developing innovative, affordable blood-based diagnostics for the early detection of Alzheimer’s disease and dementia risk. The company’s proprietary technologies, including APRON and ALZEDETECT, target deamidated human serum albumin, a novel biomarker linked to impaired amyloid-β clearance in early disease stages. ISOREA’s mission is to enable scalable, near-patient testing that supports earlier intervention and transforms global dementia prevention and care.